N-2-(Hydroxyethyl)-p-ethylphenylamin | 30573-50-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-2-(Hydroxyethyl)-p-ethylphenylamin
• 英文别名: 2-(4-Ethylanilino)ethanol
• CAS: 30573-50-3
• 化学式: C₁₀H₁₅NO
• 分子量: 165.235
• InChiKey: OWRNRKFMWWUCND-UHFFFAOYSA-N

物化性质

• 沸点：
  312.3±25.0 °C(Predicted)
• 密度：
  1.061±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• CYSTEINE PROTEASE INHIBITORS
  申请人：Unoki Gen

  公开号：US20090291945A1

  公开（公告）日：2009-11-26

  To provide a compound having an excellent cysteine protease inhibitory effect, and to provide a drug for treatment or prevention of the disease selected from the group consisting of osteoporosis, osteoarthritis, chronic rheumatoid arthritis, Paget's disease of bone, hypercalcemia, bone metastasis of cancer, and ostealgia. A compound represented by formula (1) or a pharmaceutically acceptable salt thereof, or a drug or pharmaceutical composition containing the same as an effective component.

  提供一种具有优异半胱氨酸蛋白酶抑制作用的化合物，并提供一种用于治疗或预防骨质疏松症、骨关节炎、慢性类风湿性关节炎、骨Paget病、高钙血症、骨癌转移和骨痛的药物。化合物由式（1）表示，或其药学上可接受的盐，或将其作为有效成分的药物或药物组合物。
• DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES
  申请人：Pierce C. Albert

  公开号：US20080014189A1

  公开（公告）日：2008-01-17

  The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

  本发明涉及蛋白激酶抑制剂。该发明还提供了包含本发明化合物的药物组合物以及使用该组合物治疗各种疾病的方法。
• NITROGENEOUS TRICYCLIC COMPOUND
  申请人：Asahi Kasei Pharma Corporation

  公开号：EP1829876A1

  公开（公告）日：2007-09-05

  A novel compound represented by the following formula (1) or a salt thereof [wherein R1, R5, R6, R7, and R8 represent hydrogen atom, a halogen atom, hydroxyl group, an alkyl group, an alkenyl group and the like; X1···X2 represents -CH(R2)-CH(R3)-, -CH(R2)-CH(R3)-CH(R4)-, -C(R2)=C(R3)-, or -C(R2)=C(R3)-CH(R4)- (R2, R3, and R4 represent hydrogen atom, or an alkyl group); A1, A11, A2, and A21 represent hydrogen atom, or an alkyl group; Y represents -CH(A3)-, -CH(A3)-C(A4)(A41)-, -CH(A3)-C(A4)(A41)-C(A5)(A51)-, or a single bond (A3, A4, A41, A5, and A51 represent hydrogen atom, or an alkyl group), and Z represents hydroxyl group, or -N(A6)(A61) (As represents hydrogen atom, or an alkyl group, and A61 represents hydrogen atom, an alkyl group, a substituted alkyl group and the like)], having an action of potently inhibiting phosphorylation of myosin regulatory light chain.

  由下式(1)代表的新型化合物或其盐[其中R1、R5、R6、R7和R8代表氢原子、卤素原子、羟基、烷基、烯基等；X1---X2代表-CH(R2)-CH(R3)-、-CH(R2)-CH(R3)-CH(R4)-、-C(R2)=C(R3)-或-C(R2)=C(R3)-CH(R4)-（R2、R3和R4代表氢原子或烷基）；A1、A11、A2和A21代表氢原子或烷基；Y 代表 -CH(A3)-、-CH(A3)-C(A4)(A41)-、-CH(A3)-C(A4)(A41)-C(A5)(A51)- 或单键（A3、A4、A41、A5 和 A51 代表氢原子或烷基），Z 代表羟基或 -N(A6)(A61) （As 代表氢原子、或烷基，A61 代表氢原子、烷基、取代的烷基等）]，具有有效抑制肌球蛋白调节轻链磷酸化的作用。
• ONE PACK-TYPE DENTAL ADHESIVE COMPOSITION
  申请人：Shofu Inc.

  公开号：EP3804688A1

  公开（公告）日：2021-04-14

  To provide one liquid type dental adhesive composition that exhibits excellent adhesive property to glass ceramics, oxide-base ceramics and tooth substance, and has excellent storage stability, which are contrary features. One liquid type dental adhesive composition contains (a) silane coupling agent represented by general formula (1), (b) acidic group-containing polymerizable monomer, (c) volatile organic solvent, and (d) water. (In the formula, R1 represents an organic group having at least one functional group selected from the group consisting of a (meth)acryloyl group, a vinyl group and an epoxy group, R2 represents C4-C8 linear alkyl group, R3 represents C1-C8 alkyl group, and n is integer selected from 1 to 3.)

  提供一种液态牙科粘合剂组合物，该组合物对玻璃陶瓷、氧化物基陶瓷和牙齿物质具有极佳的粘合性，并具有极佳的储存稳定性，这些特性是相反的。一种液态牙科粘合剂组合物包含（a）通式（1）代表的硅烷偶联剂，（b）含酸性基团的可聚合单体，（c）挥发性有机溶剂和（d）水。 (式中，R1 代表具有至少一个官能团的有机基团，该官能团选自(甲基)丙烯酰基、乙烯基和环氧基组成的组，R2 代表 C4-C8 直链烷基，R3 代表 C1-C8 烷基，n 是选自 1 至 3 的整数)。
• SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES
  申请人：ZYMEWORKS INC.

  公开号：US20170029490A1

  公开（公告）日：2017-02-02

  Sulfonamide-containing linkage systems for release of payload compounds from an attached targeting moiety in drug conjugates. The conjugates have the formula of [(P)-(L)]m-(T), wherein (P) is a payload compound, (L) is a linker, (T) is a targeting moiety and m is an integer from 1- to 10. Also provided are pharmaceutical compositions comprising such conjugates and there use in treating cancer.